Undisclosed MAT2A inhibitor / Anagenex - LARVOL DELTA

Anagenex Announces First Programs in Synthetic Lethal Oncology Franchise (Businesswire) - "Anagenex...announced the company has nominated PRMT5 and MAT2A as its first two preclinical programs....Anagenex’s first programs addressing PRMT5 and MAT2A fit this validated human target hypothesis. PRMT5 is a pan-essential gene and MAT2A inhibition leads to inhibition of PRMT5. Both leverage MTAP deletion, a gene that is lost in 15% of all solid tumors, providing a unique mechanism to target therapies exclusively to tumors."

New molecule • Oncology • Solid Tumor